Skip to main content
    S

    Sellas Life Sciences Group Inc (SLS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.47
    -0.39 (-4.96%)

    Market Cap: $1.60B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sellas Life Sciences Group Inc (SLS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Sellas Life Sciences Group reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$26.86M, operating cash flow was -$28.39M and free cash flow was -$28.39M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$10.09M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $28.27M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$1.00M-86.8%90.0%-4195.0%-4130.1%
    Dec 2021$7.60M+300.0%97.4%-332.8%-272.4%
    Dec 2020$1.90MN/A100.0%-893.8%-881.9%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$1.00M$7.60M$1.90M$0$0$0$0
    Cost of revenue$0$0$0$100.00K$200.00K$0$0$0$0$0
    Gross profit$0$0$0$900.00K$7.40M$1.90M$0$0$0$0
    Research and development$16.02M$19.10M$24.01M$30.27M$15.67M$9.28M$7.29M$8.77M$6.07M$11.39M
    Operating income-$28.27M-$31.51M-$37.87M-$41.95M-$25.29M-$16.98M-$20.04M-$31.09M-$23.04M-$15.99M
    Net income-$26.86M-$30.88M-$37.34M-$41.30M-$20.70M-$16.76M-$19.29M-$27.67M-$23.75M-$17.68M
    EBITDA-$27.68M-$30.95M-$37.87M-$41.62M-$20.94M-$16.80M-$19.49M-$29.55M-$22.78MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating income-$11.31M-$10.63M-$9.25M-$8.26M-$7.08M-$6.87M-$6.06M-$6.92M-$7.33M-$7.62M-$9.64M-$8.18M
    Net income-$10.09M-$9.61M-$8.41M-$7.66M-$6.79M-$6.60M-$5.81M-$6.74M-$7.11M-$7.47M-$9.57M-$8.14M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $544.00K by $71.25M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$78.34M$19.43M$6.22M$20.94M$26.27M$46.05M$16.61M$16.91M$33.53M$6.42M
    Current assets$75.21M$16.33M$3.17M$17.76M$23.04M$36.92M$8.24M$5.84M$13.09M$6.38M
    Cash and equivalents$71.79M$13.89M$2.53M$17.13M$21.36M$35.30M$7.28M$5.34M$2.32M$5.96M
    Total liabilities$7.47M$9.97M$14.20M$16.09M$5.93M$18.09M$10.52M$11.67M$31.46M$11.42M
    Short-term debt$544.00K$544.00K$446.00K$372.00K$198.00K$166.00K$217.00KN/A$8.38M$1.71M
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/A$2.61M$5.66M
    Shareholder equity$70.87M$9.46M-$7.98M$4.85M$20.35M$27.96M$6.09M$5.25M$2.07M-$5.00M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$141.09M$145.38M$114.18M$78.34M$51.55M$32.30M$34.96M$19.43M$26.50M$15.12M$24.43M$6.22M
    Total liabilities$9.29M$7.73M$6.76M$7.47M$5.92M$6.16M$7.20M$9.97M$10.61M$12.21M$14.75M$14.20M
    Cash and equivalents$134.71M$138.34M$107.10M$71.89M$44.32M$25.30M$28.40M$13.89M$21.03M$9.15M$18.41M$2.53M
    Shareholder equity$131.81M$137.66M$107.41M$70.87M$45.63M$26.15M$27.76M$9.46M$15.89M$2.91M$9.68M-$7.98M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$28.39M-$35.40M-$31.41M-$23.81M-$26.02M-$10.42M-$17.64M-$30.42M-$10.99M-$11.85M
    Capital expenditures$0$0$5.50M$4.50M$0$0$0$0$0$6.00K
    Free cash flow-$28.39M-$35.40M-$36.91M-$28.31M-$26.02M-$10.42M-$17.64M-$30.42M-$10.99M-$11.86M
    Dividends paidN/AN/AN/AN/AN/AN/A$0$487.00K$0$487.00K
    Investing cash flow$0$0-$5.50M-$4.50M$0$0$0$0$12.16M-$85.00K
    Financing cash flow$86.30M$46.76M$22.32M$24.08M$12.07M$38.44M$19.57M$23.12M$5.53M$16.50M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.94M-$7.59M-$8.85M-$4.92M-$7.07M-$7.33M-$9.07M-$7.15M-$7.81M-$9.68M-$10.76M-$4.83M
    Capital expendituresN/AN/A$0$0$0$0$0$0$0$0$0$5.50M
    Free cash flowN/AN/A-$8.85M-$4.92M-$7.07M-$7.33M-$9.07M-$7.15M-$7.81M-$9.68M-$10.76M-$10.32M
    Last 12 quarters

    Frequently Asked Questions About SLS

    What is Sellas Life Sciences Group's annual revenue?

    Sellas Life Sciences Group reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Sellas Life Sciences Group profitable?

    No. Sellas Life Sciences Group reported net income of -$26.86M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does SLS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$28.39M minus capital expenditures of $0 produced free cash flow of -$28.39M.

    How much debt does Sellas Life Sciences Group have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $544.00K and cash and equivalents of $71.79M.